• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Emergency

Prochlorperazine for migraine may lower likelihood of ED return

byJames GrayandCordelia Ross
January 26, 2015
in Emergency, Neurology, Pediatrics
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. In acute migraine, prochlorperazine administration was associated with fewer emergency department (ED) return visits when compared to treatment with other dopamine antagonists. 

2. The use of diphenhydramine was associated with an increased likelihood of return to the ED. 

Evidence Rating Level: 2 (Good)  

Study Rundown: Migraine headaches are a common presenting complaint in pediatric EDs. However, there have been very few pediatric trials comparing abortive therapies for migraine in the ED. This study retrospectively examined the treatment of migraine in children, comparing various therapies including non-opioid analgesics, dopamine antagonists, and ondansetron.

The use of non-opioid analgesics alone was associated with the lowest rate of return to ED, likely due to the lower severity of headache. Furthermore, when compared to other dopamine antagonists, prochlorperazine was associated with a lower likelihood of ED revisit. There was no significant difference in the odds of revisit when comparing ondansetron to dopamine antagonists. In addition, the use of diphenhydramine with a dopamine antagonist was associated with slightly increased odds of ED revisit. One limitation is the lack of differentiation between prophylactic diphenhydramine and the treatment of actual extrapyramidal side effects from dopamine antagonists. In addition, the study could not discern migraine severity nor the primary diagnosis for ED revisits, making it difficult to interpret the true efficacy of therapy. Nonetheless, these findings provide guidance for future investigation into abortive migraine therapies and suggest that prochlorperazine may be the most effective dopamine antagonist in acute migraine.

Click to read the study, published today in Pediatrics

RELATED REPORTS

Zavegepant (Zavzpret) may be effective for the management of migraine symptoms in Asian adults

Rimegepant (Nurtec ODT) may be an effective alternative to triptans for symptom relief in migraines

Relevant Reading: Treatment of children with migraine in emergency departments: national practice variation study. 

In-Depth [retrospective cohort study]:  This study retrospectively examined 32 124 children from 2009 to 2012 between the ages of 7 and 18 who had a primary diagnosis of migraine in the ED. Data was taken from the Pediatric Health Information System, a database of free-standing children’s hospitals. The majority of subjects (66.9%) were female and the median age at presentation was 14 years. Most patients (85%) were discharged directly from the ED and 5.5% of those had a return visit with 3 days. The use of non-opioid analgesics alone had the lowest rate of ED revisit at 4.4%. The use of prochlorperazine was associated with a lower odds of revisit when compared to metoclopramide (aOR = 1.31, CI 1.11-1.55). There was no significant difference in the odds of revisit between ondansetron and dopamine antagonists (aOR = 0.90, CI 0.77-1.07). In contrast, the use of diphenhydramine in addition to any dopamine antagonist was associated with an increased odds of revisit (aOR = 1.27, CI 1.07-1.51). Of note, only 3% of children received a triptan despite their known efficacy as abortive therapy in adults.

More from this author: Exposure to maternal depression linked to adolescent risk behaviors, Childhood ADHD, stimulant treatment not linked with height, Healthcare-associated infections falling among critically ill children, Postresuscitation care may be needed regardless of PPV duration, School-based health centers may serve as patient-centered medical homes

Image: CC

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: emergency visitsmigraine
Previous Post

Physical activity calorie equivalent menu labeling may promote exercise

Next Post

Noninvasive testing for chest pain may lead to increased invasive testing

RelatedReports

Migraine collage: a woman resting with eyes closed and a finger at her temple, a zigzag aura, window blinds and sunglasses
Chronic Disease

Zavegepant (Zavzpret) may be effective for the management of migraine symptoms in Asian adults

November 6, 2026
A woman experiencing a migraine, with visual representation of signaling pathways and a pill nearby, suggesting treatment with Rimegepant.
Chronic Disease

Rimegepant (Nurtec ODT) may be an effective alternative to triptans for symptom relief in migraines

October 6, 2026
Migraine collage: a woman resting with eyes closed and a finger at her temple, a zigzag aura, window blinds and sunglasses
Chronic Disease

Antithrombotic agents may be effective in preventing migraine in patients with patent foramen ovale

August 7, 2026
Migraine collage: a woman with her eyes closed and soft arcs radiating from her temple, a glass of water and a sleep mask
Chronic Disease

Calcitonin gene-related peptide therapies effective for chronic migraine

May 4, 2026
Next Post

Noninvasive testing for chest pain may lead to increased invasive testing

Early removal from neglect may promote normal white matter development

Early removal from neglect may promote normal white matter development

Radiation from follow-up imaging may significantly impact life expectancy

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Less social media usage is associated with improved internalizing symptoms in high-risk young adults.
  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
  • In a phase 3 trial, tirzepatide reduced BMI versus placebo in adolescents with obesity and obesity-related complications
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.